Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
4
2
2021
medline:
7
4
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
To compare the agreement between whole-body (WB) magnetic resonance (MR) imaging, 18F-FDG PET/CT, and skeletal survey (SS) in patients with multiple myeloma (MM) for diagnosis, initial staging, response evaluation, and early detection of complications. This is a retrospective cohort study including MM patients who were diagnosed, treated, and followed in 2 institutions. These patients were studied with SS, WB-MR, and/or 18F-FDG PET/CT. We studied bone lesions by anatomical locations and analyzed the concordance between SS and a tomographic technique (WB-MR or 18F-FDG PET/CT) and between both tomographic techniques (WB-MR and PET/CT). Forty-four MM patients with a mean age of 62.6 years (range, 38-85 years) were included from January 2012 to February 2016. Whole-body MR and 18F-FDG PET/CT found more lesions than SS in every location except in the skull. Concordance between WB-MR and 18F-FDG PET/CT was either good or excellent in most of the locations and in plasmacytoma studies. However, WB-MR was better than 18F-FDG PET/CT in the study of complications (medullar compression and vascular necrosis). Our results suggest the study of MM patients should include WB-MR and/or 18F-FDG PET/CT, whereas SS is only useful for the skull. Whole-body MR and 18F-FDG PET/CT are complementary techniques, because both of them show good concordance in almost every location. It is still necessary to individualize the indication of each technique according to patient characteristics.
Identifiants
pubmed: 33534256
doi: 10.1097/RLU.0000000000003512
pii: 00003072-202104000-00006
pmc: PMC7938909
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
310-322Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Fonti R, Salvatore B, Quarantelli M, et al. 18 F-FDG PET/CT, 99m Tc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med . 2008;49:195–200.
Walker RC, Brown TL, Jones-Jackson LB, et al. Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med . 2012;53:1091–1101.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol . 2014;15:e538–e548.
Rubini G, Niccoli-Asabella A, Ferrari C, et al. Myeloma bone and extra-medullary disease: role of PET/CT and other whole-body imaging techniques. Crit Rev Oncol Hematol . 2016;101:169–183.
Rajkumar V. Myeloma today: disease definitions and treatment advances. Am J Hematol . 2016;91:90–100.
Hanrahan CJ, Christensen CR, Crim JR. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. Radiographics . 2010;30:127–142.
Dimopoulos M, Terpos E, Comenzo RL, et al. International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia . 2009;23:1545–1556.
Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol . 2013;162:50–61.
Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood . 2009;114:2068–2076.
Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood . 2011;118:5989–5995.
Ferraro R, Agarwal A, Martin-Macintosh EL, et al. MR imaging and PET/CT in diagnosis and management of multiple myeloma. Radiographics . 2015;35:438–454.
Jadvar H, Colletti PM, Delgado-Bolton R, et al. Appropriate use criteria for 18 F-FDG PET/CT in restaging and treatment response assessment of malignant disease. J Nucl Med . 2017;58:2026–2037.
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging . 2015;42:328–354.
Lecouvet FE. Whole-body MR imaging: musculoskeletal applications. Radiology . 2016;279:345–365.
Dayton VD, Williams SJ, McKenna RW, et al. Unusual extramedullary hematopoietic neoplasms in lymph nodes. Hum Pathol . 2017;62:13–22.
Jeyaraj P, Venkatesan M, Nijhawan VS. Solitary extramedullary plasmacytoma of the maxillary sinus, progressing to smoldering multiple myeloma with multifocal skeletal involvement, which resolved completely following chemotherapy alone. J Maxillofac Oral Surg . 2016;15(suppl 2):229–239.
Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica . 2015;100:1254–1266.
Derlin T, Peldschus K, Münster S, et al. Comparative diagnostic performance of 18 F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol . 2013;23:570–578.
de Waal EGM, Glaudemans AWJM, Schröder CP, et al. Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting. Eur J Nucl Med Mol Imaging . 2017;44:332–341.
Nanni C, Zamagni E. Therapy assessment in multiple myeloma with PET. Eur J Nucl Med Mol Imaging . 2017;44(Suppl. 1):111–117.
Lapa C, Knop S, Schreder M, et al. 11 C-methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics . 2016;6:254–261.
Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and 18 F-fluorodeoxyglucose positron emission tomography–computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol . 2017;35:2911–2918.
Shah SN, Oldan JD. PET/MR imaging of multiple myeloma. Magn Reson Imaging Clin N Am . 2017;25:351–365.